Technology
Health
Pharmaceutical
Genprex
$1.799876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.01 (-0.49%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Genprex and other stocks, options, ETFs, and crypto commission-free!
About
Genprex, Inc. Common Stock, also called Genprex, is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. Read More It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Employees
—
Headquarters
Austin, Texas
Founded
2009
Market Cap
27.00M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
120.06K
High Today
$1.85
Low Today
$1.79
Open Price
$1.83
Volume
3.49K
52 Week High
$19.45
52 Week Low
$0.95
Collections
Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
Medical
2018 IPO
US
News
Associated PressMar 15
NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc.
Associated PressMar 14
NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring clinical-stage gene therap...
Price Paid on Robinhood
46% Lower
Right Now
52 Week Low
$0.95
Average Price Paid
$3.30
52 Week High
$19.45
Earnings
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
Expected Mar 26, After Hours